Pain Therapeutics Company Profile (NASDAQ:PTIE)

About Pain Therapeutics (NASDAQ:PTIE)

Pain Therapeutics logoPain Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company's lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company's other products is FENROCK. REMOXY is a painkiller with a formulation designed to reduce potential risks of unintended use. The Company has developed REMOXY to make oxycodone difficult to abuse yet provide approximately 12 hours of steady pain relief when used by patients. REMOXY is intended to meet the needs of healthcare prescribing opioid drugs and seeking to minimize the risks of drug diversion, abuse or accidental patient misuse. The Company's drug candidate FENROCK is an abuse-deterrent transdermal pain patch in the pre-Investigational new drug-stage of development. FENROCK is designed to provide pain relief over 72 hours.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:PTIE
  • CUSIP: 69562K10
  • Web:
  • Market Cap: $24.67 million
  • Outstanding Shares: 6,595,000
Average Prices:
  • 50 Day Moving Avg: $3.97
  • 200 Day Moving Avg: $4.15
  • 52 Week Range: $3.10 - $9.31
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.29
  • P/E Growth: -0.020
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $2.01 per share
  • Price / Book: 1.86
  • EBITDA: ($12,950,000.00)
  • Return on Equity: -75.11%
  • Return on Assets: -70.30%
  • Current Ratio: 14.21%
  • Quick Ratio: 14.21%
  • Average Volume: 40,232 shs.
  • Beta: 2.14
  • Short Ratio: 15.2

Frequently Asked Questions for Pain Therapeutics (NASDAQ:PTIE)

What is Pain Therapeutics' stock symbol?

Pain Therapeutics trades on the NASDAQ under the ticker symbol "PTIE."

When did Pain Therapeutics' stock split? How did Pain Therapeutics' stock split work?

Shares of Pain Therapeutics reverse split on Wednesday, May 10th 2017. The 1-7 reverse split was announced on Monday, May 8th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 9th 2017. An investor that had 100 shares of Pain Therapeutics stock prior to the reverse split would have 14 shares after the split.

How were Pain Therapeutics' earnings last quarter?

Pain Therapeutics (NASDAQ:PTIE) posted its quarterly earnings data on Wednesday, August, 9th. The company reported ($0.64) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.47) by $0.17. View Pain Therapeutics' Earnings History.

Who are some of Pain Therapeutics' key competitors?

Who are Pain Therapeutics' key executives?

Pain Therapeutics' management team includes the folowing people:

  • Remi Barbier, Chairman of the Board, President, Chief Executive Officer
  • Nadav Friedmann, Chief Medical and Operating Officer, Director
  • Michael Marsman Pharm.D., Senior Vice President - Regulatory Affairs
  • Robert Z. Gussin Ph.D., Independent Director
  • Michael J. O' Donnell Esq., Independent Director
  • Saira Ramasastry, Independent Director
  • Sanford R. Robertson, Independent Director
  • Patrick J. Scannon M.D., Ph.D., Independent Director

How do I buy Pain Therapeutics stock?

Shares of Pain Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pain Therapeutics' stock price today?

One share of Pain Therapeutics stock can currently be purchased for approximately $3.74.

MarketBeat Community Rating for Pain Therapeutics (NASDAQ PTIE)
Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  46 (Vote Outperform)
Underperform Votes:  67 (Vote Underperform)
Total Votes:  113
MarketBeat's community ratings are surveys of what our community members think about Pain Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Pain Therapeutics (NASDAQ:PTIE) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating
Consensus Rating:Sell (Score: 1.00)
Consensus Price Target: N/A
Consensus Price Target History for Pain Therapeutics (NASDAQ:PTIE)
Price Target History for Pain Therapeutics (NASDAQ:PTIE)
Analysts' Ratings History for Pain Therapeutics (NASDAQ:PTIE)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/17/2017GabelliDowngradeHold -> SellLowView Rating Details
(Data available from 10/24/2015 forward)


Earnings History for Pain Therapeutics (NASDAQ:PTIE)
Earnings by Quarter for Pain Therapeutics (NASDAQ:PTIE)
Earnings History by Quarter for Pain Therapeutics (NASDAQ PTIE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2017Q2 2017($0.47)($0.64)ViewN/AView Earnings Details
4/25/2017Q1 2017($0.42)($0.42)ViewN/AView Earnings Details
10/20/2016Q316($0.63)($0.56)ViewN/AView Earnings Details
7/19/2016Q216($0.98)($0.49)ViewN/AView Earnings Details
5/5/2016Q1($0.70)($0.91)ViewN/AView Earnings Details
10/30/2014Q314($0.56)$89.70 millionViewN/AView Earnings Details
8/5/2014Q214($0.49)ViewN/AView Earnings Details
5/6/2014Q1 14($0.42)($0.56)$1.96 millionViewN/AView Earnings Details
2/4/2014Q413($0.07)$5.04$2.00 million$35.24 millionViewN/AView Earnings Details
10/31/2013Q313($0.07)($0.14)$2.00 million$1.96 millionViewN/AView Earnings Details
4/24/2013Q1 2013($0.07)($0.07)$2.80 million$1.96 millionViewN/AView Earnings Details
2/6/2013Q4 2012($0.14)($0.56)$2.79 million$2.47 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Pain Therapeutics (NASDAQ:PTIE)
Current Year EPS Consensus Estimate: $-2.3500 EPS
Next Year EPS Consensus Estimate: $-2.9000 EPS


Dividend History by Quarter for Pain Therapeutics (NASDAQ PTIE)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Pain Therapeutics (NASDAQ:PTIE)
Insider Ownership Percentage: 32.70%
Institutional Ownership Percentage: 36.68%
Insider Trades by Quarter for Pain Therapeutics (NASDAQ:PTIE)
Institutional Ownership by Quarter for Pain Therapeutics (NASDAQ:PTIE)
Insider Trades by Quarter for Pain Therapeutics (NASDAQ:PTIE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/6/2013Sanford RobertsonDirectorBuy50,000$3.73$186,500.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Pain Therapeutics (NASDAQ:PTIE)
Latest Headlines for Pain Therapeutics (NASDAQ:PTIE)
Loading headlines, please wait.



Pain Therapeutics (PTIE) Chart for Tuesday, October, 24, 2017

This page was last updated on 10/24/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.